A Study of Chemoradiation and Pembrolizumab for Locally Advanced Cervical Caner

Status: open

University of Virginia & Merck (UVA-LACC-PD201) "A Randomized Phase Ii Study of Chemoradiation and Pembrolizumab for Locally Advanced Cervical Caner.

Treatment for Cervical Cancer

Contact Us Or call (251) 665-8000

Description

Inclusion Criteria: Histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, stages IB2, IIA, IIB, IIIB and IVA, Stage IB1 with + pelvic or para0aortic nodes base on MRI also eligible; no evidence of distant metastases; recurrent cervical cancer is not eligible; ECOG performance status of 0-2. Exclusion Criteria: Malignancy within the prior 5 years (exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy); diagnosis of immunodeficiency; know history of HIV, Hepatitis B/C, active TB, inflammatory bowel disease; hypersensitivity to pembrolizumab or any of its excipients; active autoimmune disease that has required systemic treatment in the past 2 years; known history or evidence of pneumonitis; known active CNS metastases and/or carcinomatous meningitis.

Sponsors

This trial is sponsored by Merck.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

  • Rocconi RodneyView Profile
    Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistInterim Director of Mitchell Cancer Institute; Chief of Gynecologic Oncology Service; Associate Director for Clinical Research, Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical Oncology
This link will open in a new tab or window.